Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Conditions
Brief summary
This is a study of Camrelizumab combined with Apatinib versus Apatinib alone in the third-line treatment of metastatic gastric cancer. Paticipants will be radomized to receive treatment of Camrelizumab combined with Apatinib or Apatinib alone. The primary study hypothesis is that the adding Camrelizumab to Apatinib can prolong the progressive-free survival of the paticipants.
Detailed description
Camrelizumab 200mg intravenously 30 - 60 min biweekly; Apatinib mesylate 250mg or 500mg oral daily continuously; The treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurred.
Interventions
DRUGCamrelizumab
a PD-1 antibody
DRUGApatinib Mesylate
an oral tyrosine kinase inhibitor
Sponsors
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients, age ≥ 18 years; 2. Patients with metastatic gastric cancer confirmed by histology or cytology; 3. Baseline blood routine and biochemical indicators meet the following criteria: 1\) Hemoglobin ≥ 9.0 g/dL; 2) Absolute neutrophil count (ANC) ≥ 1,500/mm3; 3) Platelet count≥ 100,000/mm3; 4) Total bilirubin ≤ 1.5 times the upper limit of normal value (ULN); 5) Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 ULN; 6) The international standardized ratio of prothrombin time is ≤ 1.5, and part of the thromboplastin time is within the normal range (the lower limit of 1.2 times normal value to the upper limit of 1.2 times normal value); 7) Creatinine ≤ 1.5 ULN; 8) Urine protein \<2+ (if urine protein ≥ 2+, then 24h urine protein quantitative protein must be ≤ 1g); 4．The presence of measurable lesions in patients; evaluated by investigators according to the Efficacy Evaluation Criteria (RECIST) v1.1 of Solid Tumors; 5．Eastern Tumor Collaboration Group Behavioral Status Score (ECOG PS) of 0 or 1; 6．Life expectancy ≥ 3 months; 7．The investigator assessed that the patient was able to comply with the protocol requirements; 8．Capable to sign the informed consent document.
Exclusion criteria
1. Patients who have undergone systemic chemotherapy, radiation therapy, surgery, hormone therapy or immunotherapy in the 2 weeks prior to the screening; 2. Patients with a history of taking apatinib; 3. Patients with hypertension that is difficult to control despite having been treated with multiple antihypertensive drugs (systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 90 mmHg); 4. Patients with acute coronary syndrome (including myocardial infarction and unstable angina) within 6 months prior to admission and a history of coronary angioplasty or stenting; 5. Patients with large pleural effusions or ascites requiring drainage; 6. According to NCI-CTCAE version 5.0, patients with ≥grade 3 active infections; 7. Patients with symptomatic brain metastases; 8. Patients with partial or complete gastrointestinal obstruction; 9. Patients with interstitial lung disease with symptoms or signs of activity; 10. Patients with allergies or hypersensitivity to therapeutic drugs, patients with autoimmune diseases, and have received allogeneic tissue/solid organ transplants; 11. Patients requiring systemic corticosteroids (excluding temporary use for trials, prophylactic administration for anaphylactic reactions or to reduce swelling associated with radiotherapy) or immunosuppressants, or patients who had received such therapy less than 14 days prior to admission to this study; 12. Patients with seizures who require medication; 13. Patients who undergo major surgery (open chest surgery or laparotomy, etc.), laparotomy biopsy, trauma within 28 days before registration. Registration can be carried out on the same day of the week preceding 4 weeks (however, if an artificial anastomosis is performed without bowel resection, it should be within 14 days prior to registration); 14. Patients with unhealed wounds, unhealed ulcers or unhealed fractures; 15. Patients with a history of allergies to any of the drugs studied, similar drugs or excipients; 16. Simultaneous reception of any other anti-tumor therapy, including anti-tumor proprietary Chinese medicines and immunochemicals; 17. Pregnant, lactating women, fertile but refusing to use contraception; 18. Other situations in which the investigators determined that they were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 1 year | the interval from randomization to tumor progression or death or the last follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 2 years | the interval from randomization to death of any reason or the last follow-up |
| Objective response rate | 2 years | the proportion of subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria |
| Quality of Life assessed by EORTC QLQ-OG 25 | 2 years | The Europe Organization for Research and Treatment of Cancer,Quality of Life Questionnaire-OG 25 can assess quality of life (HRQL) in patients with tumours of the oesophagus, oesophago-gastric junction and stomach. |
| Toxicity assessed by CTCAE V5.0 | 2 years | Adverse effects recorded according to CTCAE V5.0 |
Countries
China
Contacts
Primary ContactJian Xiao, PhD
Backup ContactShanshan Li, MD
Outcome results
None listed